|Mr. Karlheinz Gast||Chairman of the Management Board & CEO||N/A||N/A||N/A|
|Mr. Thomas Milz||Chief Product Officer & Deputy Chairman of Management Board||N/A||N/A||N/A|
|Mr. Thomas Zimmermann||Chief Financial Officer||N/A||N/A||N/A|
|Mr. Harald Weyand||Head of Marketing||N/A||N/A||N/A|
|Dr. Matthias Wendl||Head of Sales||N/A||N/A||N/A|
|Ms. Susanne Böhm||Head of HR||N/A||N/A||N/A|
|Dr. Olaf Randerath||Head of Medical Affairs||N/A||N/A||N/A|
|Dr. Susanne Endreß||Head of QA, Drug Safety & Regulatory Affairs||N/A||N/A||N/A|
Apontis Pharma AG markets and sells medical drugs for indication fields of internal medicine in Germany. It develops, promotes, and sells a portfolio of single pills and other pharmaceutical products with a focus on cardiovascular diseases, such as hypertension, hyperlipidemia, and secondary prevention, as well as respiratory diseases and diabetes. The company is headquartered in Monheim am Rhein, Germany.
Apontis Pharma AG’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.